Most new drugs are still too costly at launch, ICER says

A new analysis from the non-profit group found that net launch prices for new medicines spiked significantly between 2022 and 2025, and the majority were well above its cost-effectiveness guidelines.  

By Jonathan Gardner • Oct. 22, 2026

Pharma gift giving linked to writing more prescriptions — but less appropriate prescribing

The line between educating healthcare professionals and wooing them can still be fuzzy, which is impacting what doctors prescribe, according to a new analysis.

By Alexandra Pecci • Oct. 20, 2026

Lilly is fighting a black market for its new obesity drug even before it launches

The large pharma’s promising new candidate retatrutide is still in the clinic. But Lilly is already fighting a web of illicit sellers for the drug online.

By Kelly Bilodeau • Oct. 12, 2026

Pharma’s $500B patent problem will come in waves — not as a cliff

Merck is the most exposed to risk from generic competition in the short term, but AbbVie, Johnson & Johnson, Sanofi and others will also grapple with patent losses in the years to come.

By Sy Mukherjee • Oct. 8, 2026

What J&J’s Spravato patent win could mean for psychedelic drugs

As more psychedelic drugs move toward market, developers are testing how far patent protection can extend around familiar compounds.

By Kelly Bilodeau • Sept. 24, 2026

mRNA cancer vaccines’ biggest barriers to market

Manufacturing hurdles are just one challenge the industry must overcome to commercialize personalized mRNA cancer vaccines.

By Alexandra Pecci • Sept. 10, 2026

Gilead takes a ‘different’ approach to reaching the Black community with new HIV campaign

Gilead’s new “Up to Date” campaign uses humor and dating scenarios to reach Black communities amid persistent gaps in HIV prevention and PrEP use.

By Alexandra Pecci • Sept. 2, 2026

The hidden scale-out problem behind CAR-T’s growth

CAR-T’s commercial challenge isn’t making bigger batches. It’s making thousands of patient-specific manufacturing runs behave like one reliable system. In vivo aims to eliminate the batch altogether.

By Sy Mukherjee • Sept. 1, 2026

Legend’s interim CEO sees a shorter path to the next era of CAR-T

Alan Bash explains how Carvykti informed the company’s strategy and what its in vivo platform still needs to prove.

By Sy Mukherjee • Aug. 25, 2026

How cost and perception could reshape the GLP-1 market

As Eli Lilly and Novo Nordisk race for share, surveys show affordability and prescribing preferences may help decide the winners.

By Kelly Bilodeau • Aug. 19, 2026

How Helus’ new CEO plans to scale its psychedelic drug pipeline

Can Michael Halstead replicate the controlled growth he pulled off at Intra-Cellular Therapies in mental health’s psychedelic era?

By Kelly Bilodeau • Aug. 18, 2026

BMS builds big in Texas; Regeneron backs would-be rival

BMS reveals plans for a new manufacturing hub in Houston, and Regeneron invests in startup developing a Dupixent competitor.

By PharmaVoice Staff • Aug. 14, 2026

Drugs that missed the mark in pharma’s last earnings round

Why treatments from Alnylam, Merck, AbbVie and Roche stumbled in the last quarter.

By Kelly Bilodeau • Aug. 11, 2026

Brand-name drug denials are surging, especially for weight-loss

Nearly one-third of prescriptions included in a new study were rejected the first time a patient attempted to fill them.

By Alexandra Pecci • July 28, 2026

Compounders maintain a firm grip on the GLP-1 market

Despite an FDA crackdown and numerous pharma lawsuits, nearly 1 in 5 patients are taking cheaper weight-loss alternatives despite the risks.

By Kelly Bilodeau • July 17, 2026

AstraZeneca aims for a new blockbuster run in cardio disease

With a recent FDA nod for Baxfendy under its belt, AstraZeneca is looking to grow its prowess in cardio disease, weight management and beyond, according to a company exec.

By Alexandra Pecci • June 1, 2026

Who’s winning pharma’s innovation race? The rankings are out.

While Eli Lilly reigns supreme, Idea Pharma’s annual R&D ranking reveals which other large pharmas are on the rise — and which are stumbling.

By Meagan Parrish • May 22, 2026

Novo hikes guidance on Wegovy pill’s fast sales start

Sales and profit should shrink less than originally anticipated thanks to strong momentum for its new obesity pill, the drugmaker said in its most recent earnings report. 

By Kristin Jensen • May 7, 2026

Predictive analytics in pharma turns lab data into launch strategies

Explore how diagnostic insights become launch strategies with predictive analytics and real-world lab data.

April 13, 2026

The FDA’s shame game

The agency is becoming more open about its criticisms of pharma companies and leaders, raising new privacy concerns in the industry.

By Kelly Bilodeau • March 30, 2026

Can Ocugen succeed where other gene therapy makers have struggled?

The biotech aims to quickly bring three gene therapies to market, and overcome the development and commercialization challenges that have dogged the space.

By Meagan Parrish • March 27, 2026

Gilead could potentially end HIV. But will it be able to?

After launching a PrEP medication that was 100% effective in clinical trials, the company is facing a complex global rollout and leveraging its network of partners for help.

By Meagan Parrish • March 20, 2026

Novo regained weight loss footing in the pill arena — but Lilly is coming

Eli Lilly has run away with the GLP-1 market. But can Novo Nordisk maintain pole position in the oral space?

By Alivia Kaylor • March 13, 2026

Bayer sets the stage for a pharma comeback

The pharma giant’s drug sales haven’t wowed in recent years. But that could soon change.

By Meagan Parrish • Feb. 6, 2026

Why TrumpRx is stumbling before it gets off the ground

Concerns about potential kickbacks, costs and conflicts have triggered calls for oversight.

By Kelly Bilodeau • Feb. 4, 2026